Astal Labs subsidiary appoints internal, cost and secretarial auditors for FY27

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Astal Laboratories' subsidiary Sriven Pharmachem appointed three auditors for FY27
  • Mr. Balayogiswara Rao Peddinti named internal auditor; M/s Avnesh Jain & Co. as cost auditor
  • M/s Mahendra Khandelwal & Co. appointed as secretarial auditor to enhance compliance
powered bylight_fuzz_icon
52298129

*this image is generated using AI for illustrative purposes only.

Astal Laboratories Limited disclosed that its material wholly owned subsidiary, Sriven Pharmachem India Private Limited (SPIPL), has appointed three key auditors for the financial year 2026-27. The appointments were approved by SPIPL's board of directors on September 28, 2026.

The move aims to comply with the Companies Act, 2013 and strengthen the secretarial and corporate compliance functions of the subsidiary. The disclosures were made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Auditor Appointments Details

The board approved the following appointments effective for FY27:

Role Appointed Entity/Individual Location/Profile
Internal Auditor Mr. Balayogiswara Rao Peddinti Finance professional with experience in plant finance and controls
Cost Auditor M/s Avnesh Jain & Co. Jaipur-based proprietorship firm headed by Mr. Avnesh Jain
Secretarial Auditor M/s Mahendra Khandelwal & Co. Proprietorship firm of Practicing Company Secretaries

Professional Backgrounds

M/s Avnesh Jain & Co. is a cost accountancy firm with extensive experience in cost audit, budgeting, and project accounting. M/s Mahendra Khandelwal & Co., founded by CS Mahendra Prakash Khandelwal, provides services in corporate laws, SEBI regulations, and secretarial audits for listed entities. Mr. Balayogiswara Rao Peddinti brings expertise in accounts, finance, product costing, and statutory compliances.

The company stated that the relationships between directors were not applicable for these appointments as they are external auditor engagements rather than director appointments.

Historical Stock Returns for Astal Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
+1.91%-3.54%-11.75%-0.03%-30.98%+543.54%

How will the strengthened compliance framework at SPIPL impact Astal Laboratories' consolidated financial reporting accuracy for FY27?

What are the potential cost implications for Astal Laboratories given the appointment of three separate specialized audit firms?

Will the enhanced secretarial and internal audit controls at SPIPL influence future capital allocation decisions within the Astal group?

Astal Laboratories adopts FY26 financials at 33rd AGM

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights
  • Astal Laboratories Limited held its 33rd AGM on September 29, 2026, via Video Conferencing.
  • Shareholders adopted standalone and consolidated audited financial statements for FY26.
  • Maggidi Venkatesh was re-appointed as Non-Executive Director after retiring by rotation.
  • Thirty-one members participated in the meeting, which concluded at 2:22 pm IST.
powered bylight_fuzz_icon
52233360

*this image is generated using AI for illustrative purposes only.

Astal Laboratories Limited concluded its 33rd Annual General Meeting on September 29, 2026, adopting both standalone and consolidated audited financial statements for the fiscal year ended March 31, 2026. The meeting was conducted entirely through Video Conferencing and Other Audio-Visual Means, ensuring shareholder participation from remote locations.

The proceedings were chaired by Sudheer Karna Kankanala, Whole Time Director, who provided an update on the company's operational and financial activities for FY26. A total of 31 members participated in the virtual meeting, meeting the requisite quorum. The Company Secretary welcomed attendees and confirmed the availability of all statutory registers and reports for electronic inspection during the session.

Key resolutions passed

Shareholders voted on three ordinary business items via the Central Depository Services (India) Limited e-voting portal. The resolutions covered the adoption of financial reports and the re-appointment of a non-executive director retiring by rotation.

Agenda Item Resolution Type Details
Adoption of Standalone Financials Ordinary Audited statements, Board and Auditor reports for FY26
Adoption of Consolidated Financials Ordinary Audited statements, Board and Auditor reports for FY26
Director Re-appointment Ordinary Maggidi Venkatesh, Non-Executive Director, retires by rotation

Governance and attendance

The meeting saw the presence of five directors through the virtual platform, including independent directors Hemachakrapani Bangaraiahgari, Julius Paul Reinhard Paschke, and Radhakishore Pandrangi. Mahendra Prakash Khandelwal, a practicing company secretary, served as the scrutinizer for the e-voting process. The Chairman addressed shareholder queries raised by registered speakers and other participants before concluding the session with a vote of thanks.

Consolidated voting results are scheduled to be disseminated to the stock exchange and published on the company website within 48 hours of the meeting's conclusion.

Historical Stock Returns for Astal Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
+1.91%-3.54%-11.75%-0.03%-30.98%+543.54%

How does the adoption of the FY26 financial statements reflect on Astal Laboratories' revenue growth and margin trends compared to the previous fiscal year?

What strategic initiatives or capital expenditure plans were highlighted by the Whole Time Director to drive future operational expansion?

How might the re-appointment of Maggidi Venkatesh influence the company's long-term governance strategy and board dynamics?

More News on Astal Laboratories

1 Year Returns:-30.98%